Manufacturers report positive data for finerenone in phase III study

In a subanalysis of the FIDELIO-DKD study, finerenone, an oral, non-steroidal selective mineralocorticoid receptor antagonist, significantly reduced the risk cardiovascular complications vs placebo (HR=0.86, p=0.0339) in patients with chronic kidney disease and type II diabetes.

Source:

Biospace Inc.